<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01583361</url>
  </required_header>
  <id_info>
    <org_study_id>LCHEN-PLAGH</org_study_id>
    <nct_id>NCT01583361</nct_id>
  </id_info>
  <brief_title>SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer</brief_title>
  <acronym>RESONANCE</acronym>
  <official_title>Phase III, Randomized, Multicenter, Controlled Evaluation of S‐1 and Oxaliplatin as Neoadjuvant Chemotherapy for Advanced Gastric Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lin Chen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, multicenter, controlled trial to prove efficacy of S‐1 and Oxaliplatin
      as Neoadjuvant Chemotherapy for Advanced Gastric Cancer Patients who undergo D2 gastrectomy.

      The primary endpoint is three-year free disease and the second primary includes five-year
      overall survival, safety and R0 resection rate.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease free survival</measure>
    <time_frame>three years</time_frame>
    <description>SOX regimen as Neoadjuvant chemotherapy for AJCC II-III gastric cancer patients is superior than postoperative SOX after D2 surgery.Disease free survival is defined as time of surgery to recurrence or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>3 months</time_frame>
    <description>For neoadjuvant chemotherapy patients,response rate will be evaluated according to RECIST 1.1 criteria after at least 2 cycles of SOX chemotherapy.CT scan is required to every patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>five years</time_frame>
    <description>Neoadjuvant chemotherapy of SOX is superior than postoperative SOX after D2 dissection in AJCC II-III gastric cancer patients.Overall survival is defined as the time of randomization to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>six months</time_frame>
    <description>Number of participants with adverse events related to SOX chemotherapy.All adverse events are from CTCAE 4.0 criteria.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">772</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A:Neoadjuvant sox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in arm a will receive (N=2-4) cycles of neoadjuvant SOX first, and then standard gastrectomy with D2 lymphadenectomy, and (8-N) cycles of adjuvant SOX adjuvant chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B:Adjuvant SOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in arm B will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant SOX later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin+S-1</intervention_name>
    <description>S-1: 40~60mg bid，po, d1~14 （S-1：BSA &lt;1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA&gt;1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1</description>
    <arm_group_label>Arm A:Neoadjuvant sox</arm_group_label>
    <other_name>Oxaliplatin(Sanofi-aventis)</other_name>
    <other_name>S-1(Taiho)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant Oxaliplatin/S-1（SOX）</intervention_name>
    <description>S-1：40~60mg bid，d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)</description>
    <arm_group_label>Arm B:Adjuvant SOX</arm_group_label>
    <other_name>Oxaliplatin(Sanofi-aventis)</other_name>
    <other_name>S-1(Taiho)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed gastric adenocarcinoma

          2. Gastroesophageal junction tumour type II or III(NCCN 2009) can be enrolled

          3. All patients must undergo EUS,CT(or PET-CT) and laparoscopy to evaluate tumor stage
             classification (TNM), and only stage II or III (AJCC 7th) gastric cancer patients can
             be enrolled

          4. planning to undergo gastric cancer D2 surgery after neoadjuvant chemotherapy

          5. KPS &gt; 60; ECOG performance status 0-2

          6. Life expectancy &gt; 6 months

          7. Age: 20 to 75 years

          8. No other severe disease and life expectancy less than five years

          9. 7 days before enrolled, baseline data should be finished including:

               -  Granulocyte count ≥ 1.5×109/L;

               -  platelet count ≥ 100×109/L;

               -  Hemoglobin ≥ 90g/L;

               -  hepatic &lt; 1.5×ULN;

               -  total bilirubin ≤ 1.0×ULN;

               -  creatinine &lt; 1.5×ULN;

               -  PT-INR/PTT &lt; 1.7× ULN

         10. Disease had to be measurable by the Response Evaluation Criteria in Solid Tumors
             (RECIST1.1) criteria

         11. Written informed consent and able to comply with the protocol

        Exclusion Criteria:

          1. Patient cannot undergo surgery or chemotherapy because of other severe disease

          2. Be allergic to chemotherapy drugs

          3. Patients receiving any chemotherapy or drugs involved in this trial in four weeks
             before enrolled

          4. Patients received cytotoxic chemotherapy, targeted therapy, immunotherapy or
             radiotherapy for gastric cancer

          5. Within the last 5 years in patients with a history of other malignant diseases

          6. Pregnant or breast-feeding women

          7. Severe heart disease like symptoms of coronary heart disease, New York Heart
             Association (NYHA) grade II or worse congestive heart failure or cardiac arrhythmia
             having medications or myocardial infarction within the last 12 months

          8. Patients with upper gastrointestinal obstruction or absorption anomaly; patient in
             obstruction of the Helicobacter pylori failure like effect S-1 to take and absorb

          9. Patients with a history of peripheral nerve disease

         10. Patients who get organ transplant

         11. lack of dihydropyrimidine dehydrogenase (DPD)

         12. Infection or other disease failure to control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tao Li, MD,PhD</last_name>
    <phone>86-10-66938328</phone>
    <email>litbj301@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Li, MD,PhD</last_name>
      <phone>0086-10-66938328</phone>
      <email>litbj301@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2012</study_first_submitted>
  <study_first_submitted_qc>April 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2012</study_first_posted>
  <last_update_submitted>April 23, 2012</last_update_submitted>
  <last_update_submitted_qc>April 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Lin Chen</investigator_full_name>
    <investigator_title>Chief of GI Surgeon</investigator_title>
  </responsible_party>
  <keyword>two arms</keyword>
  <keyword>D2 lymphadenectomy</keyword>
  <keyword>chemotherapy before and after surgery</keyword>
  <keyword>disease free survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

